Celltrion to boost biosimilar business

Published: 2010-04-27 06:59:00

Updated: 2010-04-27 06:59:00

Celltrion Inc., the largest biopharmaceutical contract manufacturer in Asia, said in its regulatory filing on April 22 that the company has signed a contract with Singapore's state-run Temasek Holdings to receive $200 million from the latter.

Under Temasek’s investment, Celltrion plans to expa...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK